|drug1439||Heparin - Therapeutic dosage Wiki||1.00|
There is one clinical trial.
The COVID-19 infection primarily manifests itself as a respiratory tract infection, although new evidence indicates that this disease has systemic involvement involving multiple systems including the cardiovascular, respiratory, gastrointestinal, neurological, hematopoietic and immune systems. Recent studies have shown that in its pathophysiology, inflammation and thrombogenesis predominate, especially in the severe forms of COVID-19. Thus, the investigators hypothesized that the use of heparin and tocilizumab could potencially reduce inflammation and thrombogenesis in patients with severe COVID-19 infection, improving patients outcomes and survival.
Description: Proportion of patients with clinical improvement in 30 days, defined by hospital discharge or a reduction of at least 2 points compared to baseline on the ordinal scale recommended by the World Health Organization: Not hospitalized, with no limitations on activities; Not hospitalized, but limited to activities; Hospitalized, with no need for supplemental oxygen; Hospitalized, needing supplemental oxygen; Hospitalized, requiring high flow oxygen therapy, non-invasive mechanical ventilation or both; Hospitalized, requiring ECMO, invasive mechanical ventilation or both; Death.Measure: Proportion of patients with clinical improvement Time: 30 days
Description: Number of days in hospital and ICUMeasure: Hospital and ICU length of stay; Time: 30 days
Description: Rate and Time of invasive mechanical ventilationMeasure: Duration of invasive mechanical ventilation Time: 30 days
Description: Time of use of vasopressorsMeasure: Duration of vasopressor use Time: 30 days
Description: Renal failure by AKIN criteria in 30 daysMeasure: Renal failure by AKIN criteria Time: 30 days
Description: Myocardial injury; Acute myocardial infarction; Cardiogenic shock; arrhythmias; Myocarditis; Pericarditis; Ventricular dysfunction.Measure: Incidence of cardiovascular complications Time: 30 days
Description: Deep vein thrombosis and pulmonary embolismMeasure: Incidence of venous thromboembolism Time: 30 days
Description: Mortality rateMeasure: Mortality Time: 30, 60 and 90 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports